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Rapid and point-of-care tests for the diagnosis of 
Trichomonas vaginalis in women and men
Charlotte A Gaydos,1 Jeffrey D Klausner,2 Nitika Pant Pai,3 Helen Kelly,4 
Cordelia Coltart,4 Rosanna W Peeling4
AbstrAct
background Trichomonasvaginalis (TV) is a highly 
prevalent parasitic infection worldwide. It is associated 
with many adverse reproductive health outcomes. Many 
infections are asymptomatic and syndromic management 
leads to underdetection of TV. Traditional methods of 
TV detection such as wet preparation are insensitive. 
New rapid, point-of-care (POC) tests can enhance the 
diagnosis of trichomoniasis.
Methods The authors reviewed the literature and 
discuss older POC tests for TV detection, as well as the 
OSOM lateral flow test, the AmpliVue test, the Solana 
test and the GeneXpert test as well as the limitations of 
wet preparation and culture for detection of TV.
results The OSOM test is easy to perform, compared 
with other POC tests, and is Clinical Laboratory 
Improvement Amendments (CLIA)-waived, equipment-
free, has sensitivities of 83%–86% compared with 
nucleic acid amplification tests (NAATs) and can be 
performed in 15 min. The AmpliVue and the Solana 
tests are not CLIA waived and require small pieces of 
equipment. They are molecular amplified assays and 
can be completed in <1 hour. AmpliVue demonstrated a 
sensitivity for vaginal swabs of 100% compared with wet 
preparation/culture and 90.7% compared with NAATs. 
Solana demonstrated a sensitivity of 98.6%–100% 
for vaginal swabs and 92.9%–98% for female urines, 
compared with wet preparation/culture. Compared with 
other NAATs, the sensitivity for Solana was 89.7% for 
swabs and 100% for urine. The GeneXpert TV test for 
women and men is a moderately complex test, requires 
a small platform and can be performed in <1 hour. The 
sensitivity compared with wet preparation/culture for 
self-collected vaginal swabs was 96.4%, 98.9% for 
endocervical specimens and 98.4% for female urine. For 
men, sensitivity for urines was excellent (97.2%). The 
specificity for all assays was excellent.
conclusions Several rapid POC tests have the potential 
to rapidly diagnose trichomoniasis in women and one is 
available for detection of TV in men.
IntroductIon
Trichomonas vaginalis (TV) is a common motile 
protozoan parasite, which is the most prevalent 
non-viral sexually transmitted infection (STI) in 
the world and was estimated by the WHO to cause 
276.4 million new infections per year in persons 
between the ages of 15 and 49 years in 2008.1 It 
infects approximately 3.7 million people in the 
USA.2 These infections represent the most common 
curable STI in young, sexually active men and 
women.1
In women, trichomoniasis has been associated 
with poor reproductive health outcomes such as 
low birth weight (LBW) and premature birth.3–5 In 
a cohort of over 13 000 women, there was an attrib-
utable risk of trichomonas associated with LBW 
in blacks of 11% versus 1.6% in Hispanics and 
1.5% in Whites.3 Data from the National Health 
and Nutrition Examination Survey (NHANES) 
2001–2004 estimated that 3.1% of women in the 
USA are infected with TV6 and of importance over 
80% of cases were asymptomatic.7 Data from the 
NHANES also demonstrated that TV was highly 
associated with coinfections with other STIs.7 TV 
infection is also associated with twofold to three-
fold increased risk of HIV acquisition and pelvic 
inflammatory disease (PID) among HIV-infected 
women.8–11 Older age is also linked to the epidemi-
ology of trichomonas, and TV may affect over 11% 
of women age >40 years and 13% of black women 
in the USA.12 13 Cases of TV are not reportable to 
the Centrrs for Disease Control and Prevention in 
the USA, so exact surveillance prevalence data are 
lacking in the USA and worldwide data are prob-
ably underestimated.
Because infection with TV is so common and 
can be associated with such serious adverse events, 
diagnostic testing for detection of TV and treat-
ment of trichomonal infections are recommended 
for symptomatic women and men. For asympto-
matic individuals, screening is only recommended 
for HIV-positive women and is only encouraged for 
persons in such locations as sexually transmitted 
disease clinics and correctional facilities.14
The conventional methods to detect TV in vaginal 
swabs are wet mount microscopy and culture tech-
niques. Wet mount microscopy is the most common 
method for detection of TV, and although this 
technique is rapid and inexpensive, it is only about 
36%–75% sensitive compared with culture even in 
the hands of trained microscopists.15 This sensi-
tivity of culture method is less in studies than what 
can be achieved by nucleic acid amplification tests 
(NAATs).16 Thus, the use of more highly sensitive 
molecular tests is recommended for detection of TV 
in women and men,since they have higher sensitivity 
than culture. Among women, NAATs may detect a 
prevalence of threefold to fivefold higher than wet 
preparation microscopy.4 Presently, there are two 
large robotic FDA-cleared NAAT platforms, which 
are not point-of-care (POC) tests, for the detection 
of trichomonas in women. They include the Aptima 
TV assay (Hologic Gen-Probe, San Diego, Cali-
fornia, USA),12 the BD ProbeTec Qx Assay on the 
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BD Viper System (Becton Dickinson, Sparks, Maryland, USA).17 
A third NAAT is the POC assay, GeneXpert Assay18 (Cepheid, 
Sunnyvale, California, USA), which is also FDA cleared for 
detection of trichomonas in men. The authors of this review will 
discuss the literature for older and recent, rapid and POC tests 
for detection of trichomonas.
Methods
A PubMed (US National Library of Medicine and the National 
Institutes of Health) search was conducted for literature 
published between 2000 and 2016 using the search terms TV 
and diagnosis, trichomonas and POC tests and trichomonas 
rapid diagnosis.
Another excellent independent search in PubMed, MEDLINE, 
Embase, Global Health, BIOSIS and Web of Science has been 
conducted previously for literature published in January 
2004–December 2013.19
Descriptive analyses were performed using STATA V.12. For 
each study, we calculated sensitivity and specificity along with 
95% CIs, compared with the reference standard. A third PubMed 
search and review was conducted by de Cortina et al for litera-
ture published between January 2010 and August 2015.20
The manufacturers of the newer TV diagnostic rapid tests 
discussed include: the OSOM lateral flow test (Bedford, Massa-
chusetts, USA), the AmpliVue test, the Isothermal Helicase-De-
pendent AmpliVue Assay (Quidel, San Diego, California, USA), 
the Solana TV-Assay (Quidel) and the GeneXpert TV test 
(Cepheid). Culture was performed in studies by InPouch TV 
(BioMed Diagnostics, White City, Oregon, USA).
Poc laboratory diagnostic tests for detection of tV
In addition to the wet saline preparation for microscopy for 
motile trichomonads, there are older tests that have been evalu-
ated.21 These are the Affirm VPIII Microbial Identification Test 
(Becton Dickinson) and the Kalon TV latex test (Kalon Biolog-
ical, Surrey, UK). The Kalon test uses latex beads coated with 
antibodies specific to TV proteins but is not FDA cleared or 
CE (Conformité Européenne) marked in Europe.22 The Xenos-
trip-Tv (Xenotope Diagnostics, San Antonio, Texas, USA) was a 
rapid immunochromagraphic antigen detection test. It detected 
heat-stable trichomonas alpha-actinin protein in vaginal swabs. 
The patent, filed by University of Texas in 2006, included a 
saliva-based assay that was never commercialised. The vaginal 
swab studies had reported sensitivities of 78.5% and 90% in two 
published studies, but it is no longer available.23 The Xenostrip-tv 
product was later acquired by Genzyme, a Sanofi company based 
in Cambridge, Massachusetts, USA, and sold under the brand 
name, OSOM. In 2011, Genzyme sold its diagnostic products 
business to Sekisui Chemical, UK, which continues to sell the test 
as the OSOM Trichomonas rapid test.
Affirm VPIII
The first molecular assay to offer detection of trichomonas was 
the Affirm VPIII test (Becton Dickinson), which is a nucleic acid 
hybridisations test that also detects Gardnerella vaginalis and 
Candida albicans.24 It uses synthetic nucleic acid capture probes 
and colour development detection probes complementary to 
unique genetic sequences of the target organisms. This assay is 
considered a moderately complex test with at least 10 steps and 
requires 45 min to achieve results. However, when this assay was 
compared with a NAAT assay for the detection of trichomonas, 
the sensitivity was only 46%.25
OSOM Trichomonas test
This trichomonas rapid antigen test is an immunochromatographic 
capillary-flow enzyme immunoassay based on trichomonas 
membrane proteins, which can detect trichomonas in 10 min.
Compared with wet preparation and culture, OSOM Tricho-
monas test has a much improved sensitivity, excellent specificity 
and compares favourability to NAAT assays with reported sensi-
tivities of 83%–90%.15 16 26 This assay is Clinical Laboratory 
Improvement Amendments (CLIA) waived and requires five 
steps to complete. An early study compared the sensitivity and 
specificity of the OSOM test, wet mount and culture performed 
on vaginal swabs from 449 sexually active women.26 The overall 
prevalence of TV was 23.4% by the reference standards of either 
wet mount or culture test being positive. For the vaginal swabs, 
the OSOM test displayed 83.3% and 98.8% sensitivity and spec-
ificity, respectively, and it performed better than wet prepara-
tion. In another comparison with wet preparation, culture and 
a NAAT assay, the OSOM assay performed very well with a 
sensitivity and specificity of 90% and 100%, respectively, in 330 
sexually active females aged 14–21 years.16 The prevalence of 
trichomoniasis in this population was 18.5%; the sensitivity of 
wet preparation ranged from 50% to 54% and for culture was 
75%. In symptomatic women, the sensitivity of the OSOM test 
was 92.5% and for the NAAT, 97.5%. Similar low sensitivities 
for culture and wet preparation methods have been reported in 
other publications.15 27 Huppert et al has reported high accepta-
bility and accurate results when allowing adolescents to perform 
their own OSOM assay.28 29
Additionally, women have been enrolled in a research study to 
perform the OSOM assay themselves at home after ordering a 
home TV test kit via the internet; they obtained accurate results 
compared with a mailed-in NAAT assay and found the home test 
to be highly acceptable.30 Use of this assay as a standard of care 
POC test for the detection of trichomoniasis in an emergency 
department was also shown to prevent overtreatment of vaginal 
infections compared with historical controls before the introduc-
tion of the POC test, resulting in good antibiotic stewardship.31
AmpliVue assay
This new technology utilises isothermal helicase-dependent 
amplification (HDA) and has a turnaround time of approx-
imately 45 min.32 The test targets a conserved repeat DNA 
sequence of TV. The assay employs a helicase to separate DNA 
before amplification. It consists of three steps: (1) sample lysis 
preparation with dilution/heating in a heat block for 10 min at 
95°C; (2) isothermal DNA amplification of TV DNA for 25 min 
at 64°C by HDA in a heat block; and (3) lateral-flow strip-based 
colorimetric detection in a disposable device.
The AmpliVue Trichomonas assay was recently FDA cleared as 
a moderately complex test for vaginal swabs from symptomatic 
and asymptomatic women, and its potential to be CLIA waived 
may increase its usefulness as a POC test that could be used for 
the rapid diagnosis and immediate treatment of trichomoniasis 
while patients are still in the clinic.
The results from 992 women were compared with the 
results from wet preparation microscopy and/or culture, 
which comprised a composite positive comparator standard 
and demonstrated high sensitivity of 100% and specificity of 
97.9%–98.3% (table 1). The prevalence of TV by symptom 
status was asymptomatic: 9.4%, symptomatic: 17.3% and for all 
women: 12.1%. The AmpliVue Trichomonas was also compared 
with the Aptima TV NAAT assay as a reference standard. Sensi-
tivity for AmpliVue compared with Aptima was 90.7% overall 
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(90.1% for symptomatic and 87.2% for asymptomatic women). 
The overall per cent agreement versus Aptima TV was 97.8% 
(Cohen’s kappa=90.7), 97.1% for symptomatic women and 
97.7% for asymptomatic women.32
Solana Trichomonas assay
The Solana Trichomonas assay is an in vitro qualitative NAAT 
for the detection of TV for the diagnosis of trichomoniasis using 
the HDA technology and the Solana instrument.33 In order to 
detect TV directly from vaginal swab specimens, the assay targets 
a conserved repeat DNA sequence of the trichomonas genome. 
The assay consists of two steps: (1) specimen preparation and 
(2) amplification and detection of target sequence specific to the 
trichomonas genome by HDA in the presence of a target-specific 
fluorescence probe. The assay is intended for use in clinical labora-
tories but has the potential to be useful in a doctor’s office or clinic 
that has a laboratory. It was recently FDA cleared as a moderately 
complex POC assay for the diagnosis of trichomoniasis.
Results from the FDA clinical trial are summarised.33 Vaginal 
swabs and urines were obtained by clinicians from 1044 women 
of whom 501 were asymptomatic and 543 were symptomatic. 
The prevalence of TV by swabs and/or urines was 11.5%. For 
these clinician-collected swabs, the Solana Trichomonas assay 
showed high sensitivity and specificity for swabs from both 
asymptomatic (100%/98.7%) and symptomatic (98.6%/98.5%) 
women compared with a FDA-composite reference standard 
of wet preparation and/or culture for detection of TV. Urines 
were similarly sensitive and specific from asymptomatic 
(98.0%/98.4%) and symptomatic (92.9%/97.9%) women 
when compared with the FDA-composite reference methods 
(table 2).33 Compared with a NAAT assay (Aptima-TV), the 
sensitivity/specificity performance was 89.7%/99.0% for swabs 
and 100%/98.9% for urines.
GeneXpert TV assay (Cepheid)
A multicentre study of this ‘near-patient’ assay prospectively 
collected urine, endocervical swabs and patient-collected vaginal 
swabs from female subjects presenting with symptoms asso-
ciated with TV infection and subjects who were asymptom-
atic.18 Urine, endocervical swabs and patient-collected vaginal 
swabs were tested with the GeneXpert TV assay, the Gen-Probe 
APTIMA TV assay and cultured with InPouch (BioMed). The 
performance was determined relative to a patient-infected status 
(PIS) algorithm, based on results from the reference standard 
comparator tests of either culture and/or the NAAT assay being 
positive. Sequencing was performed on specimens with discor-
dant results, as allowed by the FDA.
From 1867 eligible study participants, 714 were symptomatic 
and 1153 were asymptomatic. The GeneXpert TV assay demon-
strated a sensitivity and specificity for TV on patient-collected 
vaginal swabs (n=1791) of 96.4% and 99.6%, respectively 
(table 3). Prevalence was 10.8%. For endocervical swabs, the 
GeneXpert TV assay revealed a sensitivity and specificity for TV 
(n=1799) of 98.9% and 98.9%, respectively; prevalence was 
9.8%. The GeneXpert TV assay showed a sensitivity and spec-
ificity for TV on female urine specimens (n=1793) of 98.4% 
and 99.7%, respectively; prevalence was 10.2%. There were no 
statistically significant differences in performance with respect 
to symptomatic status.18 This assay was recently FDA cleared for 
use with male urine.
dIscussIon
These POC and near-patient studies discussed herein provide 
evidence of new diagnostic options for detection of tricho-
moniasis in symptomatic and asymptomatic women, with one 
also being FDA cleared for detection of TV in urine from men. 
They indicate that the performance of new amplified testing 
methods is highly accurate and able to provide rapid turn-
around times.
The OSOM assay is the only POC assay that is CLIA waived, 
meaning it does not need to be performed in a laboratory, and 
is the only one that does not require special instrumentation. Its 
high sensitivity (83%–90%) and excellent specificity make it an 
ideal assay for resource limited settings.27 The OSOM test has 
table 1 Comparison of AmpliVue results in symptomatic and asymptomatic women to composite reference method of wet preparation and culture
symptom status n Prevalence% sensitivity % (95% cI) specificity % (95% cI) PPV  (95% cI) nPV % (95% cI)
Asymptomatic women 648 9.4 100 (94.1 to 100) 98.3 (96.9 to 99.1) 85.9 (76.0 to 92.2) 100 (99.3 to 100)
Symptomatic women 342 17.3 100 (93.9 to 100) 97.9 (95.5 to 99.0) 90.8 (81.3 to 95.7) 100 (98.6 to 100)
All women 990 12.1 100 (96.9 to 100) 98.2 (97.0 to 98.9) 88.2 (81.7 to 92.6) 100 (99.6 to 100)
NPV, negative predictive value; PPV, positive predictive value
table 2 Sensitivity and specificity of the Solana assay for Trichomonas vaginalis compared with the composite reference methods of saline wet 
mount and culture
Vaginal swabs  n sensitivity (%) (95% cI) specificity (%) (95% cI)
Asymptomatic women 501 100
92.7% to 100%
98.7
97.1% to 99.4%
Symptomatic women 543 98.6
92.3% to 99.7%
98.5
97.6% to 99.2%
97.0% to 99.3%
Total 1044 99.2
95.4% to 99.9%
98.6
97.6% to 99.2%
urine
Asymptomatic women 501 98.0
89.5% to 99.6%
98.4
96.8% to 99.2%
Symptomatic women 543 92.9
84.3% to 96.9%
97.9
96.2% to 98.8%
Total 1044 95.0
89.5% to 97.7%
98.2
97.1% to 98.8%
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been successfully used in adolescent clinics, emergency depart-
ments and self-testing programmes.28–31
The AmpliVue rapid assay demonstrated that an amplified 
molecular NAAT assay can perform as well as saline micros-
copy/culture and provided comparable results with another 
FDA cleared NAAT assay while yielding results in real time of 
45 min.32 The AmpliVue Trichomonas assay is FDA cleared as 
moderately complex; it identified all of the culture and saline 
microscopy positive cases of trichomonas infections and substan-
tially more than culture or saline microscopy, as shown by 
detecting additional confirmed positives and the strong agree-
ment with Aptima TV NAAT assay.
The Solana TV assay provided evidence that this NAAT 
molecular assay can perform as well as saline microscopy/
culture and provided comparable results as another FDA-cleared 
NAAT assay for detection of trichomoniasis in symptomatic and 
asymptomatic women while providing results in approximately 
45 min.33 This assay has the potential to be CLIA waived in the 
future, which may increase its usefulness as a POC test that can 
be used for immediate treatment of infected patients.
The GeneXpert TV assay demonstrated a very high sensitivity 
and specificity compared with a PIS of culture and/or NAAT 
assay. The sample preparation, amplification and real-time detec-
tion are all fully-automated and completely integrated in the test 
cartridge. The assay offers a rapid result in less than 40 min at the 
time the test turns positive but requires 60 min if the test result 
is negative. These results can be potentially used to treat infected 
patients in a clinic or emergency department.18 Because the assay 
is fully automated, it has the potential to achieve CLIA waiver 
in the future providing highly sensitive and specific results in 
women.33 It is the only rapid assay for detection of TV approved 
for use in men.
Because of the association of trichomonas infections with 
many adverse health events, especially adverse birth outcomes 
and perinatal morbidity,3 34 as well as its strong association with 
HIV transmission,35 36 it may be time to advocate for more testing 
and treatment of persons with trichomoniasis.37 Since we now 
have more highly accurate new POC testing methods available, 
it seems reasonable to promote more public health national and 
international recognition for trichomonas infections and support 
more testing. Redesign of clinic flow for patients that can take 
advantage of self-collected vaginal swabs may be able to take advan-
tage of the newer POC assays to facilitate treatment, so patients 
do not have to have return appointments to receive test results.37 
Additionally, since most trichomonas infections in men and women 
are asymptomatic, syndromic management programmes for symp-
tomatic patients will not be able to detect and treat those asympto-
matic-infected patients who do not have symptoms to qualify them 
for syndromic management. Furthermore, modelling and review 
studies of the potential of treatment for trichomonas to impact 
and to improve health outcomes, especially for HIV, are power-
fully intriguing.11 38 39 In summary, the newer POC tests for the 
detection of TV in clinical samples appear to far outperform the 
sensitivity of wet preparation and culture assays and can be recom-
mended for the detection of TV in clinical settings.
Key messages
 ► Trichomonas vaginalis infection is the most prevalent curable 
sexually transmitted infection but diagnostic methods are 
suboptimal.
 ► We know that an antigen detection rapid test and a few 
molecular assays are available, but there has not been 
a systematic review of their performance and operating 
characteristics.
 ► This review demonstrates that the OSOM antigen detection 
test has reasonable sensitivity and high specificity compared 
with a variety of reference tests, including wet mount, culture 
and PCR.
 ► Molecular assays like AmpliVue, Solana and the GeneXpert 
show excellent performance against laboratory-based PCR 
assays but are more expensive than antigen detection rapid 
tests.
table 3 Comparison of GeneXpert TV assay results in symptomatic and asymptomatic women compared with a patient-infected status of culture 
and/or a NAAT assay
sample type status total (n) sens spec Prev (%) PPV (%) nPV (%)
ES Symp 685 100% (71/71) 98.5% (605/614) 10.4 88.8 100
Asymp 1114 98.1% (104/106) 99.1% (999/1008) 9.5 92.0 99.8
Overall 1799 98.9% (175/177)* 98.9% (1604/1622)† 9.8 90.7 99.9
Difference p Value p=0.517 p=0.331
PC-VS Symp 682 98.6% (73/74) 99.5% (605/608) 10.9 96.1 99.8
Asymp 1109 95.0% (113/119) 99.6% (986/990) 10.7 96.6 99.4
Overall 1791 96.4% (186/193)‡ 99.6% (1591/1598)§ 10.8 96.4 99.6
Difference p Value p=0.254 p=1.000
UR Symp 688 98.6% (71/72) 99.8% (615/616) 10.5 98.6 99.8
Asymp 1105 98.2% (109/111) 99.6% (990/994) 10.0 96.5 99.8
Overall 1793 98.4% (180/183)¶ 99.7% (1605/1610)** 10.2 97.3 99.8
Difference p Value p=1.000 p=0.655
*Testing results by sequencing: 1 of 2 FN was TV positive; 1 of 2 was TV negative.
†Testing results by sequencing: 8 of 18 FP were TV positive; 10 of 18 were TV negative.
‡Testing results by sequencing: 3 of 7 FN were TV positive; 4 of 7 were TV negative.
§Testing results by sequencing: 5 of 7 FP were TV positive; 2 of 7 were TV negative.
¶Testing results by sequencing: 3 of 3 FN were TV negative.
**Testing results by sequencing: 5 of 5 FP were TV negative.
ES, endocervical swab; NAAT, nucleic acid amplification test; PC-VS, patient-collected vaginal swab; UR, urine.
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